Swiss biotech Actelion extended its lead in the pulmonary arterial hypertension market, picking up FDA approval for a follow-on treatment that should help ward off mounting competition in the space.
ZS Pharma, awaiting FDA approval for a kidney drug, saw its share value soar about 30% after Actelion confirmed that it's discussing a multibillion-dollar buyout with the company.
Actelion has presented detailed data on the drug it hopes will cement its position in the pulmonary arterial hypertension market, Uptravi. The shock-free data drove a small uptick in Actelion's stock, but fell short of being the blockbuster-guaranteeing release some were hoping to see.
Bellerophon Therapeutics has squeaked through onto the public markets with an IPO that priced below the expected range. It now has about $83 million in cash to advance a pair of pipeline candidates it gleaned from its spinoff from Ikaria in October 2013.
In an interview with Bloomberg, COO John Milligan says the big biotech outfit--which is expected to generate megablockbuster revenue from the newly approved Sovaldi for hep C--is pondering a head-to-head study to determine whether Letairis is better or worse than Actelion's recently approved lung drug Opsumit.
Christmas has arrived early for United Therapeutics. The biotech took most analysts completely by surprise with the news that the FDA had stamped an approval on Orenitram (treprostinil, or oral Remodulin) after twice snubbing its application for the pulmonary arterial hypertension drug.
Late on Friday the FDA came through with an approval for Actelion's pulmonary arterial hypertension drug Opsumit (macitentan), its next-gen successor to the franchise drug Tracleer.
Just hours after Bayer laid out some ambitious plans to accelerate development of a new wave of cancer and cardiovascular therapies, the FDA came through with a key new approval of riociguat--to be sold as Adempas--for a devastating lung disease.
An FDA panel of outside experts has contributed a round of thumbs-up for Bayer's new drug for pulmonary arterial hypertension, to be sold as Adempas, sending the pharma giant on what appears to be another victory lap in the lead-up to a likely approval.
Bayer has a new set of upbeat results from its long-term extension study of riociguat, a major new player in a busy field of competitors angling for a share of the market for pulmonary arterial hypertension.